Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results from the AIM4CML Study in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Clinical Lymphoma Myeloma and Leukemia（2024）
Key words
CML,AIM4CML,asciminib,CML-CP,oncedaily dosing,twice-daily dosing
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined